Insider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) SVP Sells 3,725 Shares of Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) SVP Larry Todd Edwards sold 3,725 shares of Arcutis Biotherapeutics stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $10.01, for a total value of $37,287.25. Following the completion of the sale, the senior vice president now owns 136,635 shares of the company’s stock, valued at $1,367,716.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Arcutis Biotherapeutics Stock Performance

Shares of Arcutis Biotherapeutics stock opened at $10.18 on Friday. The company has a market capitalization of $1.18 billion, a PE ratio of -3.47 and a beta of 1.17. The company has a 50-day simple moving average of $9.81 and a two-hundred day simple moving average of $9.50. Arcutis Biotherapeutics, Inc. has a one year low of $1.76 and a one year high of $13.17. The company has a debt-to-equity ratio of 1.09, a quick ratio of 8.19 and a current ratio of 8.46.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.06. Arcutis Biotherapeutics had a negative net margin of 150.51% and a negative return on equity of 145.41%. The firm had revenue of $30.86 million for the quarter, compared to the consensus estimate of $31.00 million. During the same quarter in the previous year, the firm earned ($1.16) EPS. Research analysts expect that Arcutis Biotherapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Arcutis Biotherapeutics

A number of large investors have recently made changes to their positions in ARQT. Pennant Investors LP acquired a new stake in shares of Arcutis Biotherapeutics in the 4th quarter worth $552,000. SG Americas Securities LLC increased its position in Arcutis Biotherapeutics by 531.2% during the 2nd quarter. SG Americas Securities LLC now owns 99,161 shares of the company’s stock valued at $922,000 after buying an additional 83,452 shares in the last quarter. AMI Asset Management Corp purchased a new stake in Arcutis Biotherapeutics in the first quarter valued at about $3,421,000. ADAR1 Capital Management LLC acquired a new stake in Arcutis Biotherapeutics in the fourth quarter worth about $888,000. Finally, Vanguard Group Inc. boosted its holdings in Arcutis Biotherapeutics by 5.5% in the first quarter. Vanguard Group Inc. now owns 5,166,417 shares of the company’s stock worth $51,199,000 after acquiring an additional 269,904 shares in the last quarter.

Analyst Ratings Changes

ARQT has been the topic of a number of research reports. Jefferies Financial Group began coverage on shares of Arcutis Biotherapeutics in a research report on Wednesday, August 28th. They set a “buy” rating and a $15.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and set a $18.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday, August 15th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $13.33.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.